Sixteen years of working inside some of the most complex, high-stakes, and often underestimated companies in healthcare has given me a front-row seat to what actually separates the ones that scale from the ones that stall. Not in theory, but in the decisions they make, the tradeoffs they navigate, and the way their businesses hold up under pressure as they grow.
We started in 2010, with the recession still in the air. No website. No business cards. I wasn’t even completely sure I was building a company. What I did know was that healthcare companies were drowning in complexity and starving for clarity, and that I had spent enough time on the inside to recognize where things were breaking long before they showed up in revenue.
Sixteen years, four exits, and hundreds of engagements later, that hasn’t changed as much as you’d expect. The companies are different, the markets evolve, and the language gets more sophisticated, but the underlying patterns that determine who builds something that actually holds, and who doesn’t, are remarkably consistent.
Over time, you start to see the same issues show up in different forms. Sometimes it shows up in positioning, sometimes in structure, and sometimes in the way growth was built in the first place.
But underneath it, the pattern is consistent.
These are the 16 lessons I see most often, and the ones companies usually don’t recognize until they’ve already started paying for them.
Revenue going up does not mean enterprise value is being built. Buyers pay for the infrastructure underneath the growth, not the growth itself. If your momentum depends on a handful of relationships, one sales rep, or a market tailwind you didn't create, it's fragile. Buyers can smell fragile from a long way off.
Every founder believes their company has enormous upside. So does every other founder sitting across from the same buyer. What differentiates a premium deal from a discounted one is evidence that what you've built will keep working without you in the room.
Most companies figure out their positioning is broken when they start losing deals. By then they've already spent months generating the wrong pipeline, attracting the wrong clients, and building the wrong case studies. Positioning is a leading indicator. If it's unclear or built for an audience you've outgrown, the revenue hit is coming. You just haven't seen it yet.
The narrative that got you your first ten clients is rarely the one that gets you to exit. Companies evolve. Their story often doesn't. I've sat with leadership teams running a completely different business than the one described on their website, their pitch deck, and in their sales conversations. That gap is one of the most expensive problems in healthcare commercialization, and almost nobody is watching for it.
The more a buyer has to work to understand your business, the lower the number they put on it. Complexity reads as execution risk. If you can't explain what you do, why it works, and who it's for in plain language, you're leaving money on the table.
Every company has a story about why they're different. The ones who win have data, client outcomes, and documented patterns that back it up. In healthcare especially, where buyers are sophisticated and have been burned before, claims without evidence get discounted immediately. Build the proof before you need it, because by the time you need it, it's too late to build it.
What makes you stand out early rarely holds as you grow. As you scale, you take on more clients, build more processes, hire more people, and the edges that made you distinct quietly get sanded off. The companies that maintain differentiation at scale do it deliberately. It doesn’t happen on its own.
I’ve watched significant budget get spent on campaigns that never had a chance, not because the creative was wrong, but because sales didn’t believe in it, leadership wasn’t reinforcing it, or it didn’t reflect how decisions were actually being made in the market. Alignment is about aligning on how the business actually wins. Without that, marketing generates activity, not pipeline.
If the company only grows when you're personally selling it, that's a practice, not a company. Buyers know this. Investors know it. Building a commercial engine that operates independently of your personal relationships is one of the hardest transitions a founder makes. Most wait too long to start.
Fast execution on the wrong strategy doesn't save time. It compounds the problem. I've seen companies move with impressive speed in entirely the wrong direction, then spend twice as long unwinding it. Speed is only a competitive advantage when you're clear on where you're going.
Early traction is earned by being scrappy, relational, and willing to do things that don't scale. Premium acquisitions are earned by having built something that does. The skills required are different, the mindset is different, and assuming the same approach will carry you all the way through is one of the most common mistakes I see.
In healthcare especially, the first question a sophisticated buyer asks is where this could go wrong. Regulatory exposure. Customer concentration. Key person dependency. Reimbursement vulnerability. Map and address your risk profile before going to market, or someone else will map it for you and use it to negotiate you down.
Every company that becomes a category leader looks inevitable in hindsight. It never was. Behind every durable brand in healthcare is a team that chose, again and again, to stay in the room when it was hard — building the positioning, the proof, the relationships, and the reputation even when nobody was watching. The companies that last are the ones that keep showing up.
Value doesn't accumulate naturally over time just because you've been in business. It has to be built through deliberate choices about revenue quality, customer concentration, margin structure, IP development, and commercial infrastructure. Companies that understand this start early. The ones who don't are always surprised when the buyer's number comes in lower than expected.
This is the one that surprises people most, because complexity can feel like sophistication. It isn't. The companies that command premium valuations are the ones whose business model, value proposition, and competitive position can be explained clearly in five minutes. Clarity is a valuation driver.
By the time you're in a formal M&A process, most of the work that determines your outcome is already done. The brand you built, the clients you won, the team you assembled, the proof points you documented, and the story you honed were all created years before the deal. The companies that exit well don't prepare for a transaction. They build something worth buying and let the transaction be the easy part.
Sixteen years goes fast when you're in it. Slower when you're early and it feels like nothing is working, and then impossibly fast once it starts to compound.
If any of these lessons are landing for you right now, that's exactly why we built what we built.
We're not done building.
— Dr. Roxie Mooney, Founder & CEO, Legacy DNA
Legacy DNA partners with mid-market healthcare, pharmacy, and healthtech companies to build the commercial systems that turn growth into enterprise value and premium outcomes.
If you’re building something that needs to scale, align, and hold its value, let's talk.
We're growing revenue consistently. Isn't that enough to command a strong valuation?
Not on its own. Revenue growth tells buyers what's happening, it doesn't tell them whether it will keep happening without you. The questions that drive premium multiples are underneath the growth: Is it repeatable? Is it systemized? Is it dependent on a handful of relationships or one strong sales rep? Buyers pay for the infrastructure beneath the momentum, not the momentum itself. If that infrastructure isn't there, the number will reflect it.
How do I know if my company's story is still working?
The clearest signal is usually a gap between what's on your website and what you actually sell, between how your team describes the business and how your buyers describe it, between the clients you're attracting and the clients you actually want. Most companies don't catch this until they're losing deals they expected to win. By then, the wrong pipeline has already been built. Positioning is a leading indicator. If your story was written for a company you were three years ago, it's costing you now.
What's the biggest mistake founders make when preparing for an exit?
Starting too late. By the time you're in a formal M&A process, most of what determines your outcome is already done. The proof points, the brand, the team, the commercial infrastructure — buyers are evaluating all of it before a single number is put on paper. The founders who exit well didn't prepare for a transaction. They built something worth buying, consistently, over time, and let the transaction be the easy part.
We have a compelling vision and strong clinical outcomes. Why aren't buyers responding the way we expected?
Because buyers aren't underwriting your vision. They're underwriting their confidence in what happens after the deal closes. Clinical outcomes matter, but only when they're documented, repeatable, and translatable into a business model that holds up without the founder in the room. A compelling vision gets you in the conversation. Proof, clarity, and predictability determine what you walk out with.
How is Legacy DNA different from a traditional marketing or consulting firm?
We don't separate commercialization from valuation strategy. Why? Because they're the same work. Most firms help you look better in the market. We help you build the underlying systems, story, and proof that buyers and investors actually reward with higher multiples. We've been inside four exits. We know what the deal room looks for, and we work backward from that outcome from day one.
